Evidence map›Paper›PMID 41021082›Full record

GuidelineHead and neck pathology2025

High-Risk HPV Testing in Head and Neck Carcinoma: Key Updates from the 2025 College of American Pathologists Guideline.

William C Faquin, James S Lewis, Beth Beadle, Justin A Bishop, Rebecca D Chernock, Jeffrey F Krane, Joel T Moncur, James W Rocco, Mary R Schwartz, Raja R Seethala

Abstract readReviewPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

William C Faquin *Department of Pathology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, WRN 219, Boston, MA, 02114, USA. Wfaquin@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-1174-3972
James S Lewis *Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Beth BeadleDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Justin A BishopDepartment of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
Rebecca D ChernockDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Jeffrey F KraneDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Joel T MoncurOffice of the Director, The Joint Pathology Center, Silver Springs, MD, USA.
James W RoccoDepartment of Otolaryngology- Head and Neck Surgery, Ohio State University Wexner Medical Center, Columbus, OH, USA.
Mary R SchwartzDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA.
Raja R SeethalaDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-risk human papillomavirus (HPV) plays a significant role in the pathogenesis of certain head and neck (HN) cancers, especially squamous cell carcinomas (SCC) arising in the oropharynx. Distinction between HPV-independent and HPV-associated HNSCC has important implications for clinical management and patient prognosis in specific anatomic subsites of the head and neck. In 2018, the College of American Pathologists (CAP) issued 14 evidence-based guideline statements related to the testing, application, interpretation, and reporting of HPV and surrogate marker testing for HN carcinomas. Since that time, significant amounts of new data have been published which serves as the foundation for the updated 2025 CAP Guideline resulting in 16 evidence-based recommendations. These statements refine issues related to the application of high-risk HPV testing in patients with HNSCC, and they address some issues not fully covered in the 2018 CAP Guideline. This brief review discusses the changes that were made to the original guideline and provides a quick reference for the testing recommendations across head and neck sites.

Indexed as

Head and Neck NeoplasmsPapillomavirus InfectionsSquamous Cell Carcinoma of Head and NeckHumansHead and neckHPVOropharynxp16RNA ISHSinonasal carcinomaSquamous cell carcinomaTesting

Identifiers

PMID41021082
PMCPMC12480157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.